Rudy Li
Stock Analyst at Wolfe Research
(4.96)
# 19
Out of 5,156 analysts
39
Total ratings
70.27%
Success rate
88.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Rudy Li
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Initiates: Outperform | $40 | $26.09 | +53.32% | 5 | Feb 24, 2026 | |
| ALKS Alkermes | Initiates: Outperform | $45 | $28.45 | +58.17% | 1 | Feb 24, 2026 | |
| AXSM Axsome Therapeutics | Initiates: Outperform | $230 | $164.49 | +39.83% | 1 | Feb 24, 2026 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $60 | $62.76 | -4.40% | 5 | Feb 24, 2026 | |
| STOK Stoke Therapeutics | Initiates: Outperform | $40 | $38.31 | +4.41% | 5 | Feb 24, 2026 | |
| QURE uniQure | Initiates: Peer Perform | n/a | $17.99 | - | 1 | Feb 24, 2026 | |
| DNLI Denali Therapeutics | Initiates: Peer Perform | n/a | $21.31 | - | 1 | Feb 24, 2026 | |
| PRAX Praxis Precision Medicines | Initiates: Outperform | $500 | $309.01 | +61.81% | 4 | Feb 24, 2026 | |
| NBIX Neurocrine Biosciences | Initiates: Outperform | $160 | $129.93 | +23.14% | 1 | Feb 24, 2026 | |
| DFTX Definium Therapeutics | Initiates: Outperform | $25 | $18.35 | +36.24% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $22.58 | +46.15% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 | $80.46 | -0.57% | 3 | Jan 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3 | $1.25 | +140.00% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $21.99 | -31.79% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $2.88 | +1,288.89% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 | $9.81 | +83.49% | 7 | Aug 28, 2025 |
Centessa Pharmaceuticals
Feb 24, 2026
Initiates: Outperform
Price Target: $40
Current: $26.09
Upside: +53.32%
Alkermes
Feb 24, 2026
Initiates: Outperform
Price Target: $45
Current: $28.45
Upside: +58.17%
Axsome Therapeutics
Feb 24, 2026
Initiates: Outperform
Price Target: $230
Current: $164.49
Upside: +39.83%
Xenon Pharmaceuticals
Feb 24, 2026
Initiates: Outperform
Price Target: $60
Current: $62.76
Upside: -4.40%
Stoke Therapeutics
Feb 24, 2026
Initiates: Outperform
Price Target: $40
Current: $38.31
Upside: +4.41%
uniQure
Feb 24, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $17.99
Upside: -
Denali Therapeutics
Feb 24, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $21.31
Upside: -
Praxis Precision Medicines
Feb 24, 2026
Initiates: Outperform
Price Target: $500
Current: $309.01
Upside: +61.81%
Neurocrine Biosciences
Feb 24, 2026
Initiates: Outperform
Price Target: $160
Current: $129.93
Upside: +23.14%
Definium Therapeutics
Feb 24, 2026
Initiates: Outperform
Price Target: $25
Current: $18.35
Upside: +36.24%
Feb 24, 2026
Initiates: Outperform
Price Target: $33
Current: $22.58
Upside: +46.15%
Jan 2, 2026
Maintains: Buy
Price Target: $80
Current: $80.46
Upside: -0.57%
Sep 29, 2025
Initiates: Buy
Price Target: $3
Current: $1.25
Upside: +140.00%
Sep 29, 2025
Initiates: Buy
Price Target: $15
Current: $21.99
Upside: -31.79%
Sep 29, 2025
Initiates: Buy
Price Target: $40
Current: $2.88
Upside: +1,288.89%
Aug 28, 2025
Maintains: Buy
Price Target: $18
Current: $9.81
Upside: +83.49%